The proton therapy research beamline at the Christie NHS foundation trust
Proton therapy is a relatively new modality for cancer treatment and has several open research questions, particularly in the biological realm. Due to large infrastructure costs the modality is reserved for specialist treatment, limiting the patient outcome dataset. This requires supplementation with fundamental research through<i>in vitro</i>and<i>in vivo</i>systems. Similarly, the safety and potential benefits of new treatments, such as FLASH, should be demonstrated in lab environments prior to clinical translation. Greater access to clinically relevant research platforms is required. This work presents the capabilities of the Manchester proton therapy research facility for experimentalists' assessment to meet their research goals. Details of the research beamline geometry are presented, along with workflows for<i>in vitro</i>sample irradiation within an automated sample handling environmental chamber. Absolute dose and dose depth of the proton research beamline was measured. The dose calibration across a range of energies and dose rates is presented and fits are mathematically described. Methods to convert measured, or planned, dose to sample dose are presented including for biological studies investigating end of proton range effects. Elements of the beam optics, impacting on spot size and therefore field homogeneity, were measured for sample irradiation and beam model development. A Monte Carlo beam model was established to predict physically difficult measurements and is compared to measurements throughout. Achievable dose rates for FLASH are presented alongside absolute dosimetric accuracy. There was a focus on radiobiological research in establishing the beamline. Special care was taken to develop high-throughput repeatable<i>in vitro</i>irradiation workflows, with an adjacent radiobiological lab for immediate processing. This will lead to a reduction in experimental uncertainties seen in the literature with demonstrated accurate dosimetry, tight environmental control, and a high degree of versatility. The infrastructure presented in this work is a unique facility in the UK.
Authors
- Nicholas T. Henthorn (ORCID: https://orcid.org/0000-0002-9670-7638)
- Ranald I. Mackay (ORCID: https://orcid.org/0000-0002-7329-6127)
- K.J. Kirkby (ORCID: https://orcid.org/0000-0002-0901-210X)
- Samuel Ingram (ORCID: https://orcid.org/0000-0002-1786-349X)
- Michael J. Merchant (ORCID: https://orcid.org/0000-0001-8422-5255)
- M. J. Taylor (ORCID: https://orcid.org/0000-0002-8718-3684)
- John-William Warmenhoven (ORCID: https://orcid.org/0000-0002-3638-7759)
- S. Manger (ORCID: https://orcid.org/0000-0002-4475-2066)
Institutions
- Cockcroft Institute (GB)
- Manchester Academic Health Science Centre (GB)
- Daresbury Laboratory (GB)
- University of Manchester (GB)
- The Christie NHS Foundation Trust (GB)
Publication Details
- Journal
- Biomedical Physics & Engineering Express
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1088/2057-1976/addbe8
- Primary Topic
- Radiation Therapy and Dosimetry
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Research UK
- Horizon 2020 Framework Programme
- Manchester Biomedical Research Centre
- Engineering and Physical Sciences Research Council
- Science and Technology Facilities Council